Table 1.
Measure | Assessment time main effect | Continuation treatment main effect | Treatment × time interaction | ||||||
---|---|---|---|---|---|---|---|---|---|
df | F | p | df | F | p | df | F | p | |
SAS-SR | 9,1157 | 133.92 | <.001 | 2,236 | 0.21 | .809 | 18,1157 | 1.27 | .199 |
IIP | 9,1164 | 86.64 | <.001 | 2,237 | 1.90 | .152 | 18,1164 | 1.04 | .415 |
DYS | 9,606 | 8.23 | <.001 | 2,148 | 0.32 | .728 | 18,606 | 1.05 | .401 |
RIFT | 33,4105 | 38.22 | <.001 | 2,237 | 0.05 | .948 | 66,4105 | 0.97 | .536 |
Note. N = 241 patients who had higher-risk response to acute-phase cognitive therapy and were randomized to 8 months of continuation treatment (cognitive therapy, fluoxetine, or placebo) and followed up to 24 additional months. For the Social Adjustment Scale—Self-Report (SAS-SR), Inventory of Interpersonal Problems (IIP), and Dyadic Adjustment Scale (DYS), 10 assessments occurred at intake to acute-phase cognitive therapy and approximately every 4 months thereafter. For the Range of Impaired Functioning Tool (RIFT), functioning estimates were computed at acute-phase intake, randomization, and for each month 1–32 after randomization. Tabled results are from repeated-measures multilevel models. Multilevel models controlled receipt of non-protocol treatment.